EA201200037A1 - THERAPEUTIC COMBINATIONS OF NICOTINIC ACID AND MELDONIA - Google Patents

THERAPEUTIC COMBINATIONS OF NICOTINIC ACID AND MELDONIA

Info

Publication number
EA201200037A1
EA201200037A1 EA201200037A EA201200037A EA201200037A1 EA 201200037 A1 EA201200037 A1 EA 201200037A1 EA 201200037 A EA201200037 A EA 201200037A EA 201200037 A EA201200037 A EA 201200037A EA 201200037 A1 EA201200037 A1 EA 201200037A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nicotinic acid
meldonium
blood
meldonia
pharmaceutically acceptable
Prior art date
Application number
EA201200037A
Other languages
Russian (ru)
Other versions
EA021344B1 (en
Inventor
Иварс Калвиньш
Анатолий Бирман
Марис Веверис
Антон Лебедев
Анатолий Миснов
Original Assignee
Тетра Сиа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from LVP-09-116A external-priority patent/LV14266B/en
Application filed by Тетра Сиа filed Critical Тетра Сиа
Priority claimed from LVP-10-94A external-priority patent/LV14462B/en
Publication of EA201200037A1 publication Critical patent/EA201200037A1/en
Publication of EA021344B1 publication Critical patent/EA021344B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Настоящее изобретение содержит синергетическую комбинацию никотиновой кислоты и мелдония, отличающуюся повышенной эффективностью при лечении заболеваний, которые включают агрегацию тромбоцитов, дислипидемию, гиперлипидемию, атеросклероз, ишемическую болезнь сердца, выбранную из группы стенокардия и инфаркт миокарда, преходящее и постоянное нарушение мозгового кровообращения, включая цереброваскулярное расстройство и инсульт и периферическое окклюзионное поражение артерии, и отличающуюся пониженным эффектом прилива крови и/или увеличения содержания глюкозы в крови, которая содержит в качестве активных компонентов никотиновую кислоту или ее фармацевтически приемлемую соль и мелдоний или его фармацевтически приемлемую соль, обладающие эффективностью для указанного назначения.The present invention contains a synergistic combination of nicotinic acid and meldonium, which is highly effective in the treatment of diseases that include platelet aggregation, dyslipidemia, hyperlipidemia, atherosclerosis, coronary heart disease, selected from the group of angina pectoris and myocardial infarction, transient and permanent cerebrovascular disease, including cerebrovascular disease, including and stroke and peripheral occlusive lesion of the artery, and characterized by a reduced effect of a rush of blood and / or values of glucose in the blood, which contains nicotinic acid or its pharmaceutically acceptable salt and meldonium or its pharmaceutically acceptable salt, which are effective for this purpose, as active components.

EA201200037A 2009-06-25 2010-06-21 Therapeutic combinations of nicotinic acid and meldonium EA021344B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LVP-09-116A LV14266B (en) 2009-06-25 2009-06-25 A novel therapeutically combination of nicotinic acid and meldonium
PCT/LV2010/000008 WO2010151096A1 (en) 2009-06-25 2010-06-21 Therapeutic combinations of nicotinic acid and meldonium
LVP-10-94A LV14462B (en) 2010-06-21 2010-06-21 A combination medicinal product for inhibition of platelet aggregation

Publications (2)

Publication Number Publication Date
EA201200037A1 true EA201200037A1 (en) 2012-10-30
EA021344B1 EA021344B1 (en) 2015-05-29

Family

ID=42663684

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200037A EA021344B1 (en) 2009-06-25 2010-06-21 Therapeutic combinations of nicotinic acid and meldonium

Country Status (3)

Country Link
CN (1) CN102802618B (en)
EA (1) EA021344B1 (en)
WO (1) WO2010151096A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV14606B (en) * 2011-05-17 2013-01-20 Tetra, Sia Novel factor xii inhibitor
LV14963B (en) * 2013-06-28 2015-10-20 Tetra, Sia Corrector of endothelial dysfunction
CN104161769B (en) * 2014-08-16 2016-01-20 广州一品红制药有限公司 A kind of compositions containing adenosine cyclophosphate and application thereof
CN104622883B (en) * 2015-01-12 2017-12-05 青岛市中心医院 Pharmaceutical preparation for treating atherosclerosis and preparation method thereof
CN104622882B (en) * 2015-01-12 2017-12-05 青岛市中心医院 For treating the medical composition and its use of atherosclerosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0821587A4 (en) 1995-04-19 1999-05-19 Lipoprotein Technologies Inc Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
DE60226881D1 (en) 2001-08-20 2008-07-10 Zlb Bioplasma Ag HIGH-DENSITY LIPOPROTEIN FOR THE TREATMENT OF IMPACT AND ISCHEMIA STATE
US20070105793A1 (en) * 2005-11-04 2007-05-10 Curt Hendrix Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease

Also Published As

Publication number Publication date
CN102802618B (en) 2014-06-18
EA021344B1 (en) 2015-05-29
WO2010151096A1 (en) 2010-12-29
CN102802618A (en) 2012-11-28

Similar Documents

Publication Publication Date Title
EA201291336A1 (en) SUBSTITUTED 5-FLUOR-1H-PYRAZOLOPIRIDINE AND THEIR APPLICATION
CL2014000504A1 (en) Compounds derived from substituted condensed pyrimidines; preparation procedure; pharmaceutical composition; and use in the treatment and / or prevention of heart failure, angina pectoris, hypertension, among other diseases.
EA201500448A1 (en) GUANIDINE CONNECTION
EA201190217A1 (en) SUBSTITUTED 2-ACETAMIDO-5-ARIL-1,2,4-TRIAZOLONES AND THEIR APPLICATION
EA201290836A1 (en) RELATED BIS-ARYL ARYLTRIAZOLONES AND THEIR APPLICATION
EA201592256A1 (en) DERIVATIVES OF IMIDAZOPIRROLIDINONE AND THEIR APPLICATION IN THE TREATMENT OF DISEASES
EA201592250A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseases
EA201390060A1 (en) ANNELED PYRIMIDINES AND TRIAZINES AND THEIR APPLICATION FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES
EA201590073A1 (en) ANTI-VIRUS COMPOUNDS
EA201491060A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
PE20121617A1 (en) OXAZINE DERIVATIVES AS BACE INHIBITORS
UA111588C2 (en) JAK INHIBITOR COMPOSITION FOR LOCAL APPLICATION
BRPI1012116A2 (en) pharmaceutical composition for the treatment of heart disease
EA201101479A1 (en) NEW P2X7R ANTAGONISTS AND THEIR APPLICATION
EA201400392A1 (en) DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPIRIDAZINES AS AGONISTS Rev-Erb
EA201390826A1 (en) PYRIMIDINOUS CONNECTIONS FOR USE IN TREATING DISEASES OR STATES MEDIATED BY Lp-PLA
EA201200037A1 (en) THERAPEUTIC COMBINATIONS OF NICOTINIC ACID AND MELDONIA
EA201291167A1 (en) SUBSTITUTED HETEROCYCLYLBENZYLPYRAZOLES AND THEIR APPLICATION
EA201490610A1 (en) CONNECTIONS AND METHODS OF STRENGTHENING CONGENITAL IMMUNE RESPONSES
EA201592254A1 (en) DERIVATIVES OF Pyrazolopyrrolidin-4-IT and THEIR APPLICATION IN THE TREATMENT OF DISEASE
EA201101194A1 (en) APPLICATION OF ROSUVASTATIN LACTOL AS A MEDICINE PREPARATION
EA201300034A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IMATINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, AND WAYS TO OBTAIN THEM
EA201170190A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING EXTRACT OF PIG BRAIN
EA201492271A1 (en) CHROMAN CONNECTIONS
EA201270653A1 (en) ANTAGONIST DPI ITS APPLICATION

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM